Therapeutic Effects of Qifangfeixian Granules on Pulmonary Fibrosis in Patients with Interstitial Lung Disease.

IF 1.5 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Medical Science Pub Date : 2025-09-30 DOI:10.1007/s11596-025-00106-3

Lu-Qin Yang, Hui-Lan Zhang, Yong-Hao Li

{"title":"Therapeutic Effects of Qifangfeixian Granules on Pulmonary Fibrosis in Patients with Interstitial Lung Disease.","authors":"Lu-Qin Yang, Hui-Lan Zhang, Yong-Hao Li","doi":"10.1007/s11596-025-00106-3","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the curative effect of the Qifangfeixian granule on interstitial lung disease (ILD).Methods: This study combined animal experiments and clinical trials. Pathological changes in bleomycin (BLM)-induced pulmonary fibrosis in mice were assessed using hematoxylin and eosin (H&E), Masson, and Sirius Red staining. In the clinical study, 40 ILD patients were enrolled, with 20 in the control group and 20 in the treatment group. The treatment group received Qifangfeixian granules in addition to standard therapy for 12 weeks. Pulmonary function parameters, including forced vital capacity (FVC, L), FVCpred%, diffusing capacity for carbon monoxide (DLCO, mmol/min/kPa), and DLCOpred%, were measured before and after treatment.Results: Compared with those of the control group, the inflammatory infiltration and collagen fibres in the BLM group were significantly increased, and the inflammatory infiltration and collagen fibres in the BLM group were significantly reduced after Qifangfeixian granule treatment. Compared with those in the control group, the lung function parameters in the treatment group were significantly improved. Specifically, the FVC increased by +0.10 ± 0.18 L in the treatment group, whereas the control group showed a decrease of -0.05 ± 0.21 L (P = 0.008). Additionally, FVCpred% was improved significantly in the treatment group (+2.6% ± 5.3%) compared with the control group (-2.0% ± 6.7%, P = 0.009).Conclusion: Qifangfeixian granules can improve not only the pulmonary fibrosis of BLM-induced model mice but also the pulmonary function of patients with ILD in practice, and their clinical efficacy is accurate.","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11596-025-00106-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the curative effect of the Qifangfeixian granule on interstitial lung disease (ILD).

Methods: This study combined animal experiments and clinical trials. Pathological changes in bleomycin (BLM)-induced pulmonary fibrosis in mice were assessed using hematoxylin and eosin (H&E), Masson, and Sirius Red staining. In the clinical study, 40 ILD patients were enrolled, with 20 in the control group and 20 in the treatment group. The treatment group received Qifangfeixian granules in addition to standard therapy for 12 weeks. Pulmonary function parameters, including forced vital capacity (FVC, L), FVC_pred%, diffusing capacity for carbon monoxide (DLCO, mmol/min/kPa), and DLCO_pred%, were measured before and after treatment.

Results: Compared with those of the control group, the inflammatory infiltration and collagen fibres in the BLM group were significantly increased, and the inflammatory infiltration and collagen fibres in the BLM group were significantly reduced after Qifangfeixian granule treatment. Compared with those in the control group, the lung function parameters in the treatment group were significantly improved. Specifically, the FVC increased by +0.10 ± 0.18 L in the treatment group, whereas the control group showed a decrease of -0.05 ± 0.21 L (P = 0.008). Additionally, FVC_pred% was improved significantly in the treatment group (+2.6% ± 5.3%) compared with the control group (-2.0% ± 6.7%, P = 0.009).

Conclusion: Qifangfeixian granules can improve not only the pulmonary fibrosis of BLM-induced model mice but also the pulmonary function of patients with ILD in practice, and their clinical efficacy is accurate.

查看原文本刊更多论文

芪方肺仙颗粒治疗间质性肺病肺纤维化的疗效观察。

目的：观察芪方肺仙颗粒治疗间质性肺疾病（ILD）的疗效。方法：动物实验与临床试验相结合。采用苏木精和伊红（H&E）染色、Masson染色和Sirius Red染色评价博来霉素（BLM）诱导小鼠肺纤维化的病理变化。临床研究共纳入40例ILD患者，其中对照组20例，治疗组20例。治疗组在标准治疗的基础上给予七方肺仙颗粒治疗，疗程12周。测定治疗前后肺功能参数，包括用力肺活量（FVC， L）、FVCpred%、一氧化碳弥散量（DLCO, mmol/min/kPa）、DLCOpred%。结果：与对照组比较，七方肺仙颗粒治疗后，BLM组炎症浸润和胶原纤维明显增加，BLM组炎症浸润和胶原纤维明显减少。与对照组比较，治疗组肺功能参数均有明显改善。其中，治疗组FVC升高+0.10±0.18 L，对照组降低-0.05±0.21 L （P = 0.008）。治疗组FVCpred%较对照组（-2.0%±6.7%,P = 0.009）显著提高（+2.6%±5.3%）。结论：七方肺仙颗粒在实际应用中不仅能改善blm诱导模型小鼠的肺纤维化，还能改善ILD患者的肺功能，临床疗效准确。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Medical Science Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

4.70

自引率

0.00%

发文量

126

期刊介绍： Current Medical Science provides a forum for peer-reviewed papers in the medical sciences, to promote academic exchange between Chinese researchers and doctors and their foreign counterparts. The journal covers the subjects of biomedicine such as physiology, biochemistry, molecular biology, pharmacology, pathology and pathophysiology, etc., and clinical research, such as surgery, internal medicine, obstetrics and gynecology, pediatrics and otorhinolaryngology etc. The articles appearing in Current Medical Science are mainly in English, with a very small number of its papers in German, to pay tribute to its German founder. This journal is the only medical periodical in Western languages sponsored by an educational institution located in the central part of China.